Abstract. Because IL-4 and CpG oligodeoxynucleotides (CpG-ODNs) are immune stimulants, we evaluated the antitumor effects of IL-4 gene therapy and CpG-ODN treatment in a poorly immunogenic murine cancer model. We used a murine colorectal cancer MC38 cell line overexpressing the IL-4 gene (MC38-IL4). Incubation with MC38-IL4 and CpG-ODN enhanced bone marrow-derived dendritic cell (DC) maturation in vitro. In addition, interferon (IFN)-γ production was significantly increased in naïve splenocytes after they were coincubated with MC38-IL4 and CpG-ODN. When mice bearing MC38 wild-type tumors were inoculated subcutaneously with MC38-IL4 cells and CpG-ODN, the outgrowth of established parental tumors was significantly suppressed compared to those in the MC38-IL4-treated group (IL-4 vs. IL-4 + CpG-ODN, P= 0.015). A marked infiltration of CD8 + cells in the established parental tumors of mice treated with MC38-IL4 and CpG-ODN was confirmed by immunohistochemical analyses (MC38-IL4, 2.8±1.9 cells/field vs. MC38-IL4 + CpG-ODN, 20.7±15.3 cells/field, P=0.027). Significant tumor-specific cytolysis was detected when splenocytes of MC38-IL4 + CpG-ODN-treated mice were stimulated by γ-irradiated MC38-IL4 cells and CpG-ODN twice weekly in vitro and used as effector cells in a chromium-release assay (32.2±3.5% for MC38 cells vs. 3.2±1.1% for YAC-1 cells; at an effector to target ratio of 40). These results suggest that IL-4 and CpG-ODN treatment promotes potent Th1-type antitumor immune responses. Therefore, the combination of IL-4 gene therapy and CpG-ODN treatment for cancer should be evaluated in clinical trials.
Introduction
Several original treatments of cancer have been developed in the last decade. Many anticancer drugs, including moleculetargeted drugs, have been applied clinically. Although some of these drugs have dramatically changed the prognoses of a number of diseases, several harmful side effects were observed. Because cancer immunotherapy is thought to induce few adverse events compared to other therapies, such as chemotherapy and radiation, the establishment of novel treatments that elicit potent immune responses against cancer has been anticipated. Indeed, many clinical trials of such treatments have been conducted. However, most of them have shown only minimal effects, and immunotherapy has not yet been applied as a conventional clinical treatment for cancer. Moreover, patients with advanced cancer exhibit impaired immune responses. Therefore, new strategies are needed to induce more potent antitumor immunities.
We have previously reported the antitumor effects and mechanisms of cell-based immunotherapies that were combined with treatments with cytokines, such as interferon (IFN)-α (1-3), IL-4 (4) and IL-12 (1) . The administration of each cytokine gene-transduced tumor cells appears to induce potent cellular immune responses. However, the antitumor immune response mechanisms that were induced by these cytokine therapies differ from each other. In particular, we reported that IL-4 treatment resulted in unique and interesting biological effects.
IL-4, which is a type-2 response inducer (5,6), plays a major role in both B-cell and T-cell development in the immune system (7) . In addition, it causes a class switch of B cells, upregulates MHC class II and adhesion molecules, and prevents the apoptosis of T cells (8) . With respect to the antitumor effects, IL-4 has a direct inhibitory effect on tumor cell growth in vivo and in vitro (9, 10) and an antiangiogenic effect (11) . It has been reported that IL-4 activates endothelia in the tumor microenvironment, which results in an increased infiltration of immune cells (12) . Other reports have suggested
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that eosinophils and neutrophils are responsible for the antitumor effects induced by IL-4 (13) (14) (15) . In addition, a recent study demonstrated that local IL-4 delivery at the site of vaccination activates local dendritic cells (DCs), which play a critical role in the initiation, promotion, and regulation of host immune responses and promote type-1 T-helper (Th1) cell responses (16) . In that investigation, IL-4 appeared to support DC maturation and enhance IL-12p70 secretion from DCs. Because these findings support the therapeutic effects of IL-4 on tumors, IL-4 has been applied in the clinical treatment of tumors (17, 18) . The potent immunomodulator CpG is present at the expected frequency of about 1 in 16 bases in bacterial DNA, but it is hardly observed in vertebrate DNA. It has been reported that DNA vaccines and synthetic oligodeoxynucleotides (ODN) containing an unmethylated CpG motif promote Th1-type immune responses. CpG stimulates DCs through the toll-like receptor 9 and enhances DC maturation, which may improve therapeutic effects on established tumors. Recently, we reported the synergistic effects of the combination of CpG-ODN and IFN-α on DC maturation (19) . Furthermore, DC-based therapy with CpG-ODN and IFN-α exhibited potent antitumor effects by inducing tumor-specific cytotoxic T-lymphocyte (CTL) responses (3) .
Although we have previously demonstrated that IL-4 promotes a Th1-type antitumor immune response, evidence of the induction of a more potent immune response that diminishes established tumors in vivo is required before justification of a clinical trial. In the present study, we anticipated that the combination of IL-4 gene therapy and CpG-ODN would have additive effects on tumors. Thus, we investigated the antitumor effects of the combination therapy and the underlying mechanisms of these effects in order to determine whether the combined therapy would be appropriated in a clinical trial.
Materials and methods
Mice. Female C57BL/6 (B6) mice that were 6-8 weeks old were purchased from Sankyo Lab Service (Tokyo, Japan) for use in experiments when they were 8-12 weeks old. Mice were maintained in an animal care facility at Showa University. This study was approved by the Ethics Committee for Animal Experiments of Showa University (permission #2011-1111).
Cell lines, culture medium and reagents. The MC38 murine colorectal adenocarcinoma cell line (B6 mouse origin) and the YAC-1 lymphoma cell line were maintained in RPMI-1640 medium that was supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 IU/ml penicillin, and 100 µg/ml streptomycin (complete medium; CM) in a humidified incubator with 5% CO 2 in air at 37˚C. All cell culture reagents were purchased from Life Technologies Corp. (Gaithersburg, MD). CpG-ODN-1826 and non-CpG-ODN-1911 (used as control ODN) were synthesized by Sigma-Aldrich Japan (Tokyo, Japan). We confirmed that non-CpG-ODN-1911 did not affect DC maturation or have antitumor activity (19) .
Genetically modified tumor cell lines. The MC38 tumor cells that were transduced using retroviral vectors according to standard protocols, as previously described (20) , were selected for antibiotic resistance in CM containing 0.5 mg/ml G418 (Sigma-Aldrich Corp., St. Louis, MO). We have established a IL-4-overexpressing MC38 cell line (MC38-IL4), which produces a large amount of IL-4 (359.9±108.2 ng/10 6 cells/48 h) (4). A neomycin-resistant gene-transduced MC38 (MC38-Neo) cell line was used as a control (21) . The growth rate of the MC38-IL4 cells did not differ from those of MC38-wild-type (WT) or MC38-Neo cells in vitro.
Phenotypic changes of DCs after coincubation with IL-4-overexpressing tumor cells and CpG-ODN. In order to observe the immunogenic effects of IL-4 and CpG-ODN on DC maturation, flow cytometry was performed using FACSCalibur (Nippon Becton-Dickinson Co., Ltd., Tokyo, Japan). Bone marrow-derived DCs were generated, as previously reported (2) . We incubated the DCs (5x10 6 -6x10 6 cells/flask) with either MC38-IL4 or MC38-Neo cells (1x10 6 cells) that were 100 Gy-irradiated in combination with 6 µg/ml of either CpG-ODN-1826 or non-CpG-ODN-1911 in vitro. After a 24-h incubation, cells were harvested and stained with fluorescein isothiocyanate (FITC)-conjugated monoclonal antibodies. The monoclonal antibodies used in this assay were FITCconjugated anti-H-2Kb, I-Ab, CD80, and CD86 antibodies (obtained from Nippon Becton-Dickinson). The results were shown as ratios of the mean fluorescent intensity (MFI) of the DCs that were incubated with each monoclonal antibody to the MFI of DCs incubated with the FITC-conjugated control IgG antibody.
IFN-γ and IL-10 production in naïve splenocytes coinoculated with IL-4-overexpressing tumor cells and CpG-ODN in vitro.
In order to assess the effects of IL-4 and CpG-ODN on immune balance, we performed an enzyme-linked immunosorbent assay (ELISA) of the representative Th1-type cytokine, IFN-γ and the representative Th2-type cytokine, IL-10. Splenocytes (1x10 6 cells/ml) from naive mice were stimulated with either MC38-IL4 or MC38-Neo cells (1x10 5 cells/ml) either alone or in combination with 6 µg/ml of CpG-ODN-1826 or non-CpG-ODN-1911 in vitro. After a 24-h incubation, we measured the concentrations of IFN-γ and IL-10 in the supernatant of each culture with ELISA using a commercially available kit, according to the manufacturer's instructions (mouse IFN-γ ELISA and mouse IL-10 ELISA, Thermo Fisher Scientific, Inc., Rockford, IL). This experiment was repeated twice.
Combination therapy of IL-4-overexpressing tumors with
CpG-ODN in therapeutic models. In order to evaluate the in vivo therapeutic effects of the combination of IL-4-overexpressing tumor cells and CpG-ODN on established tumors, we measured the size of established MC38-WT tumors in mice before and after treatment, as previously described (21) . In brief, B6 mice were first injected s.c. with Immunohistological analysis. For leukocyte detection in tumor tissues, B6 mice were injected s.c. with 3x10 5 MC38-Neo or -IL4 cells with or without 30 µg/mouse of CpG-ODN-1826 in the area surrounding the established wild-type tumor 7 days after inoculation with 3x10 5 MC38-WT cells. Tumor tissues, which were harvested 3 days after inoculation with the genetically modified tumor. Serial 5-µm sections were exposed to anti-Gr-1, anti-CD11c, anti-CD4, and anti-CD8a antibodies (Nippon Becton-Dickinson). Rat IgG2a was used as a control antibody. Immunostaining was completed with a Vectastain ABC kit (Vector Laboratories, Inc., Burlingame, CA). Immunoreactive cells were counted in 6 fields in a light microscope (magnification, x400) in a blinded fashion.
Induction of tumor-specific CTL.
We assessed the tumorspecific cytolytic activity of immune mice. Mice were initially immunized with MC38-IL4 cells in combination with 30 µg of either CpG-ODN-1826 or non-CpG-ODN-1911 on Day 0, and they were then inoculated with 3x10 5 MC38-WT cells on Day 7. Subsequently, MC38-immune mice received a challenge of 1x10 6 MC38-WT cells on Day 28. Splenocytes (3x10 6 cells/ml) were harvested from these mice on Day 42, and they were then stimulated in vitro with irradiated (100 Gy) MC38-IL4 tumor cells (3x10 5 cells/ml) and 6 µg/ml of nonCpG-ODN-1911 (IL-4 group) or IL4 cells in combination with 6 µg/ml of CpG-ODN-1826 (IL-4 + CpG group). Seven days later, responder cells (1x10 6 cells/ml) were restimulated with irradiated-IL4 tumor cells either alone (IL-4 group) or in combination with 6 µg/ml of CpG-ODN-1826 (IL-4 + CpG group) that was supplemented with irradiated syngeneic naive splenocytes (30 Gy, 1x10 6 cells/ml) as well as 50 IU/ml recombinant mouse IL-2 (Nippon Becton-Dickinson). Cytolytic assays were performed 6 days after the last stimulation using the responder cells as effector cells. Naïve splenocytes that were stimulated twice in vitro with irradiated-IL4 tumor cells and CpG-ODN as described above were used as control effector cells.
Cytolytic assays. Cytolytic assays were performed as previously described (22) . Tumor-stimulated effector cells were assessed for cytolytic activity against MC38-WT and YAC-1 cells, which are sensitive to non-specific killing, in triplicate in 4-h 51 Cr-release assays. The percentage of lysis was determined using the following formula: (release in assay -spontaneous release) x 100/(maximum release -spontaneous release). Maximum release was determined by the lysis of labeled target cells with 1% Triton X-100. Spontaneous release, which was measured by incubating target cells in the absence of effector cells, was <10% of maximum release.
Statistical analyses. Significance was assessed by Student's t-tests. Differences between groups were considered significant when the P-value was <0.05.
Results

Maturation of DCs was induced by coincubation with IL-4-overexpressing tumor cells and CpG-ODN.
We investigated the effects of IL-4 and CpG-ODN on DC maturation by flow cytometry. While the coincubation of DCs with MC38-IL4 , CD80, and CD86 molecules on the DCs was clearly upregulated (Fig. 1) . These results suggest that IL-4 and CpG-ODN have synergistic effects on DC maturation.
The combination of IL-4-overexpressing MC38 cells and CpG-ODN promotes the production of Th1-type cytokines by naïve splenocytes in vitro.
Since the combination of IL-4 and CpG-ODN enhanced DC maturation, we observed their effects on naïve splenocytes. ELISAs confirmed that naïve splenocytes produced high amounts of IFN-γ after a 24-h coincubation with MC38-IL4 and CpG-ODN-1826 ( Fig. 2A) , whereas IFN-γ production could not be detected after coincubation with either IL-4 or CpG-ODN alone. While IL-10 production was clearly detected when naïve splenocytes were incubated with CpG-ODN (Fig. 2B) , coincubation with MC38-IL4 suppressed the production of IL-10. These results suggest that the combination of IL-4 and CpG-ODN promoted Th1-type immune responses.
Therapeutic inoculation of IL-4-overexpressing MC38 cells and CpG-ODN reduces the outgrowth of established tumors in vivo.
Next, we observed whether CpG-ODN had additive antitumor effects on the effects of IL-4 on established tumors in vivo. We treated tumor-bearing mice with MC38-IL4 and CpG-ODN-1826 and compared the parental tumor size. As shown in Fig. 3A , the combination therapy of MC38-IL4 (3x10 5 Cr-release assay) against MC38 or YAC-1 cells was performed 6 days after the second stimulation. Results are reported as mean % cytotoxicity ± SD. E:T, effector to target. lated with IL-4 and CpG-ODN revealed marked cytolysis that was specific for MC38-WT cells (32.2±3.5% for MC38 vs. 3.2±1.1% for YAC-1; at effector to target ratio, E:T=40). Although tumor-specific cytolysis was also detected when the splenocytes of immunized mice that had been inoculated with MC38-IL4 cells and non-CpG-ODN-1911 in vivo were stimulated with MC38-IL4 cells in vitro, the specific lysis was lower compared to that of the splenocytes of mice treated with IL-4 and CpG-ODN (15.8±2.1% for MC38 vs. 0.3±0.3% for YAC-1; E:T=40, P=0.002 when compared with IL4 + CpG for lysis of MC38). Naïve splenocytes stimulated with IL-4 + CpG-ODN did not show any MC38-specific killing (Fig. 5) . The results suggested that immunization with IL-4 and CpG-ODN effectively induce tumor-specific immune response in vivo.
Discussion
In this study, we observed that the combination of IL-4 and CpG-ODN enhanced the expression of MHC and costimulatory molecules on the surface of DCs. In addition, the combination promoted IFN-γ production and suppressed IL-10 production in naïve splenocytes in vitro, which strongly suggested that the combination of IL-4 and CpG-ODN contributed to T-cell differentiation towards a Th1-type immune response. The combined therapy of IL-4 and CpG effectively suppressed the outgrowth of parental tumors in vivo compared to IL-4 monotherapy. The results of both the immunohistochemical and the tumor-specific cytolysis analyses suggested that Th1-type immune responses were strongly induced in mice treated with IL-4 and CpG-ODN.
IL-4, which is a representative Th2-type cytokine, is produced by Th2-type cells. The Th2-type response is thought to suppress the generation of Th1 cells (23) , which are usually involved in antitumor immunity. However, it has been reported that IL-4 shows multiple suppressive effects on tumors, and our previous investigation showed that IL-4 gene transduction in MC38 cells did not affect in vitro tumor growth, while tumors were not seen in most mice injected with IL-4-overexpressing MC38 cells. This observation implies that IL-4 does not injure MC38 cells directly but reduces their tumorigenicity by inducing host immune responses. Our previous study and other investigations have suggested that IL-4 recruits and activates granulocytes in the microenvironment of parental tumors in order to attack and kill the tumor cells during the primary response. However, how IL-4 recruits or stimulates granulocytes in the tumor microenvironment remains unclear (4, 24) . Thus, IL-4 induces tumor-specific cellular immune responses, which contribute to long-lasting immunity against the parental tumors.
For further improvement of the antitumor effects of IL-4-based immune therapy, we performed combination therapy, which consisted of IL-4 with CpG-ODN, and this combination has been reported as a potent inducer of immune responses. As previously reported, treatment with CpG-ODN alone did not reduce tumor outgrowth (3) . Although CpG-ODN is thought to promote the induction of Th1-type cytokines, CpG-ODN promoted IL-10 production by naïve splenocytes in our system. Reports show that CpG induces Th2-type cytokines in certain conditions support our observation (25, 26) . MC38-IL4 did not promote IL-10 production, whereas exogenous IL-4 might. We speculate that irradiated tumor cells modified the immune circumstances in the culture. In any case, we suggest that the balance of Th1/Th2 cytokine production is critical to the induction of potent immune responses in the early stages of tumor development and that the great suppression of outgrowth of the parental tumors that was seen in this study occurred because the combination of IL-4 and CpG enhanced IFN-γ production and suppressed IL-10 production. Further investigation is required in order to clarify the mechanisms by which IL-4 reduces the IL-10 production that is induced by CpG.
However, opposite effects of IL-4 on tumors have also been reported. IL-4 itself may affect tumor growth, especially on those that have abundant IL-4 receptors. The levels of expression of the IL-4 receptor correlated with the tumorigenic potential in a murine model (27) . Several tumors appeared to be resistant to apoptosis, which is induced by chemotherapeutic agents or CD95 ligation, in an IL-4-dependent manner. IL-4 seemed to modify the immunological functions of effector cells. The cultivation of naïve CD8 + T cells in the presence of IL-4 resulted in poor cytolytic function in the cells by reducing the levels of perforin and granzymes (27, 28) . Whether an immune response is predominantly Th1 or Th2 may depend on a number of other factors, such as mouse strain, kind of tumor, amount of tumor antigen, and the amount of cytokine (29, 30) .
It has been reported that the combination of CpG, IL-4, and CD40 ligand effectively induce CTLs by enhancing the expression of immunogenic molecules on B-cell precursor acute lymphoblastic leukemia cells (31) . Although MHC class I molecules were slightly upregulated by IL-4 transduction in MC38 cells, changes in other molecules, such as costimulatory and MHC class II molecules, could not be detected in our system (unpublished data). It was thought that IL-4 and CpG-ODN resulted in antitumor effects by inducing Th1-type immune responses, especially that of tumor-specific CTLs, rather than by modulating the immunogenic molecules in the tumor cells. The mechanism by which cytokines and immunomodulators exhibit antitumor effects may also depend on the models used in the experiments.
In order to perform tumor-based gene therapy, there are a number of issues, such as dose determination, site of therapeutic injection, and therapeutic interval, that need to be determined, but the most critical issue is the establishment of the patient's cytokine gene-transduced tumor cells. The development of a new technique that transduces a targeted gene to a patient's cells may be required.
Finally, we found in this study that combination therapy with IL-4 and CpG-ODN had potent antitumor effects on established tumors through the induction of potent Th1-type immune responses in the hosts. Thus, this combination therapy may be a candidate for clinical cancer therapy, but further investigation is needed before clinical trials. 
